European Medicines Agency’s CHMP recommends granting of extension of indication for Pfizer and BioNTech COVID-19 vaccine (Comirnaty) to include use in children aged 12 to 15 in EU

Comirnaty was evaluated in trial of 2260 children aged 12 to 15 years which showed that vaccine was 75 to 100% effective at preventing COVID-19 and immune response was comparable to that in 16 to 25 age group. MHRA has not yet issued a recommendation for UK.

European Medicines Agency